MedTrace Logo

An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS

NCT00206648 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 271

Last updated 2014-12-31

No results posted yet for this study

Summary

The purpose of this study is to determine the difference in preventing a relapse between Betaseron and Avonex. Patients with RRMS currently treated with Avonex will be randomized into 2 equal-size arms; one arm will continue on the standard dose of Avonex; one arm will be converted to Betaseron standard dose.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Betaferon/Betaseron

Betaseron 250 µg SC every other day

DRUG

Betaferon/Betaseron

Avonex 30 µg IM once per week

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Completion
2005-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206648 on ClinicalTrials.gov